首页 > 最新文献

Oncologia i radiologia Kazakhstana最新文献

英文 中文
DYNAMICS OF MORBIDITY AND MORTALITY IN MALIGNANT NEOPLASMS OF THE HEAD AND NECK IN THE WORLD AND THE REPUBLIC OF UZBEKISTAN 世界和乌兹别克斯坦共和国头颈部恶性肿瘤发病率和死亡率动态
Pub Date : 2022-03-31 DOI: 10.52532/2521-6414-2022-1-63-4-10
J. Alimov, N. Karimova
Relevance: According to GLOBOCAN 2020, the number of newly reported cases of head and neck tumors worldwide, without division by sex and age, was 369,980 cases, with the number of deaths – 367,285 people. The incidence of malignant neoplasms (MN) of the head and neck is growing steadily in the Republic of Uzbekistan and worldwide. In the Republic of Uzbekistan, the head and neck MN prevalence increased in natural figures from 2,906 cases in 2016 to 2,951 cases in 2020, with a growth by 45 cases compared to 2016. The study aimed to assess the epidemiological trends of head and neck tumors in the world and the Republic of Uzbekistan in 2015-2020. Materials and Methods: The global situation with head and neck tumors was analyzed based on GLOBOCAN data. The object of the study was statistical data on all cases of head and neck malignancies in the Republic of Uzbekistan according to the reported data provided by oncological institutions, according to the adopted state form of accounting and reporting documentation Ministry of Health of the Republic of Uzbekistan No. 7ССВ “Information on diseases of malignant neoplasms.” In the Republic of Uzbekistan, an assessment of the incidence, prevalence, and mortality from MN of the head and neck was carried out with the definition of trends and the average annual average age of patients with head and neck tumors. Results: World trends in morbidity and mortality from head and neck malignancies show differences depending on the territories and the level of economic development. In 2020, 13,552 deaths from head and neck malignancies were recorded in Uzbekistan (including 6323 and 7229 in male and female patients, respectively). The mortality rate from head and neck malfunctions per 100,000 population of the Republic of Uzbekistan was 40.0‱₀, which is 0.35% higher than in 2019 and 28.7% higher than in 2009. Conclusion: Analysis of the epidemiological situation in terms of head and neck malignancies in the Republic of Uzbekistan showed a tendency towards an increase in this disease. This determines the need for further research on the diagnostics of head and neck malignancies.
相关性:根据GLOBOCAN 2020,全球新报告的头颈部肿瘤病例数(不按性别和年龄划分)为369,980例,死亡人数为367,285人。在乌兹别克斯坦共和国和全世界,头颈部恶性肿瘤(MN)的发病率正在稳步增长。在乌兹别克斯坦共和国,头颈部MN的自然患病率从2016年的2906例增加到2020年的2951例,与2016年相比增加了45例。该研究旨在评估2015-2020年世界和乌兹别克斯坦共和国头颈部肿瘤的流行病学趋势。材料与方法:基于GLOBOCAN数据分析全球头颈部肿瘤情况。研究的目的是根据肿瘤机构提供的报告数据,根据乌兹别克斯坦共和国卫生部通过的国家会计和报告文件形式7ССВ号"恶性肿瘤疾病信息",收集乌兹别克斯坦共和国所有头颈部恶性肿瘤病例的统计数据。在乌兹别克斯坦共和国,对头颈部MN的发病率、流行率和死亡率进行了评估,确定了头颈部肿瘤患者的趋势和平均年平均年龄。结果:世界头颈部恶性肿瘤发病率和死亡率的趋势因地区和经济发展水平而异。2020年,乌兹别克斯坦记录的头颈部恶性肿瘤死亡人数为13 552人(其中男性和女性患者分别为6323人和7229人)。乌兹别克斯坦共和国头颈部故障死亡率为40.0‰,比2019年高0.35%,比2009年高28.7%。结论:对乌兹别克斯坦共和国头颈部恶性肿瘤的流行病学情况分析表明,这种疾病有增加的趋势。这决定了需要进一步研究头颈部恶性肿瘤的诊断。
{"title":"DYNAMICS OF MORBIDITY AND MORTALITY IN MALIGNANT NEOPLASMS \u0000OF THE HEAD AND NECK IN THE WORLD AND THE REPUBLIC OF UZBEKISTAN","authors":"J. Alimov, N. Karimova","doi":"10.52532/2521-6414-2022-1-63-4-10","DOIUrl":"https://doi.org/10.52532/2521-6414-2022-1-63-4-10","url":null,"abstract":"Relevance: According to GLOBOCAN 2020, the number of newly reported cases of head and neck tumors worldwide, without division by \u0000sex and age, was 369,980 cases, with the number of deaths – 367,285 people. The incidence of malignant neoplasms (MN) of the head and neck \u0000is growing steadily in the Republic of Uzbekistan and worldwide. In the Republic of Uzbekistan, the head and neck MN prevalence increased in \u0000natural figures from 2,906 cases in 2016 to 2,951 cases in 2020, with a growth by 45 cases compared to 2016. \u0000The study aimed to assess the epidemiological trends of head and neck tumors in the world and the Republic of Uzbekistan in 2015-2020. \u0000Materials and Methods: The global situation with head and neck tumors was analyzed based on GLOBOCAN data. The object of the study was \u0000statistical data on all cases of head and neck malignancies in the Republic of Uzbekistan according to the reported data provided by oncological institutions, according to the adopted state form of accounting and reporting documentation Ministry of Health of the Republic of Uzbekistan No. 7ССВ \u0000“Information on diseases of malignant neoplasms.” In the Republic of Uzbekistan, an assessment of the incidence, prevalence, and mortality from MN \u0000of the head and neck was carried out with the definition of trends and the average annual average age of patients with head and neck tumors. \u0000Results: World trends in morbidity and mortality from head and neck malignancies show differences depending on the territories and the level \u0000of economic development. In 2020, 13,552 deaths from head and neck malignancies were recorded in Uzbekistan (including 6323 and 7229 in male \u0000and female patients, respectively). The mortality rate from head and neck malfunctions per 100,000 population of the Republic of Uzbekistan was \u000040.0‱₀, which is 0.35% higher than in 2019 and 28.7% higher than in 2009. \u0000Conclusion: Analysis of the epidemiological situation in terms of head and neck malignancies in the Republic of Uzbekistan showed a tendency \u0000towards an increase in this disease. This determines the need for further research on the diagnostics of head and neck malignancies.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83580804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ASPECTS OF RADIOTHERAPY OF BREAST CANCER METASTASES TO THE BRAIN: A LITERATURE REVIEW 乳腺癌脑转移的放射治疗:文献综述
Pub Date : 2022-03-31 DOI: 10.52532/2663-4864-2022-1-63-56-63
А. Almabek, D. Kaidarova, V. Kim, I. Khussainova
Relevance: Breast cancer is one of the most common diseases among women in developed countries worldwide. Breast cancer ranks first in incidence and third in mortality among malignant neoplasms in women. Despite many advances in breast cancer treatment, the prognosis for patients with metastatic breast cancer remains poor. The life expectancy of these patients is usually about one year. The accuracy of diagnosis and determining the number and sizes of oligometastases by contrasted brain MRI or PET-CT with methionine is vital for effective cancer treatment. The emergence of treatment techniques, such as stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRSR), significantly improved the disease prognosis. The use of high-tech radiation therapy in patients with oligometastases from breast carcinoma improves local control of intracranial lesions, prevents death, maintains the quality of life, and improves overall survival. The study aimed to analyze the results of key prospective studies on aspects of radiation therapy for breast cancer metastases to the brain. Methods: This review included key randomized trials on using radiation therapy for breast cancer metastases in the brain. The search was conducted in the PubMed database for 2005-2020 by the keywords “radiation therapy,” “breast cancer,” and “brain metastases.” Results: Reduced treatment time due to stereotactic radiosurgery and radiotherapy allows for maintaining productive life without expressed neurological symptoms. SRS is efficient in patients with up to five oligometastases in breast cancer. More metastases require total brain exposure, which is a poor prognostic factor. In prospective studies, SRS in breast cancer with brain metastases is recommended to improve the quality of life. Conclusion: The treatment of breast cancer with brain metastases requires a multidisciplinary approach based on the prevalence of the process, previous therapy, general somatic status, comorbidities, and available therapy options. Systemic therapy for breast cancer patients with brain metastases follows several schemes that demonstrate their therapeutic effectiveness.
相关性:乳腺癌是全世界发达国家妇女中最常见的疾病之一。在妇女恶性肿瘤中,乳腺癌的发病率排名第一,死亡率排名第三。尽管乳腺癌治疗取得了许多进展,但转移性乳腺癌患者的预后仍然很差。这些患者的预期寿命通常在一年左右。通过脑MRI或PET-CT与蛋氨酸的对比诊断和确定寡转移灶的数量和大小的准确性对有效的癌症治疗至关重要。立体定向放射外科(SRS)和立体定向放射治疗(SRSR)等治疗技术的出现,显著改善了疾病的预后。在乳腺癌少转移患者中使用高科技放射治疗可以改善对颅内病变的局部控制,防止死亡,维持生活质量,并提高总体生存率。该研究旨在分析乳腺癌脑转移放射治疗方面的关键前瞻性研究结果。方法:本综述纳入了使用放射疗法治疗乳腺癌脑转移的关键随机试验。在2005-2020年的PubMed数据库中,搜索关键词是“放射治疗”、“乳腺癌”和“脑转移”。结果:由于立体定向放射外科和放射治疗减少了治疗时间,可以在没有表现出神经症状的情况下维持生产生活。SRS对乳腺癌中有5个低转移灶的患者有效。更多的转移需要全脑暴露,这是一个不良的预后因素。在前瞻性研究中,建议对脑转移的乳腺癌患者进行SRS以改善生活质量。结论:乳腺癌脑转移的治疗需要基于过程的普遍性、既往治疗、一般躯体状态、合并症和可用治疗方案的多学科方法。乳腺癌脑转移患者的全身治疗遵循几种方案,证明其治疗效果。
{"title":"ASPECTS OF RADIOTHERAPY OF BREAST CANCER METASTASES TO THE BRAIN: A LITERATURE REVIEW","authors":"А. Almabek, D. Kaidarova, V. Kim, I. Khussainova","doi":"10.52532/2663-4864-2022-1-63-56-63","DOIUrl":"https://doi.org/10.52532/2663-4864-2022-1-63-56-63","url":null,"abstract":"Relevance: Breast cancer is one of the most common diseases among women in developed countries worldwide. Breast cancer ranks \u0000first in incidence and third in mortality among malignant neoplasms in women. Despite many advances in breast cancer treatment, the \u0000prognosis for patients with metastatic breast cancer remains poor. The life expectancy of these patients is usually about one year. The \u0000accuracy of diagnosis and determining the number and sizes of oligometastases by contrasted brain MRI or PET-CT with methionine \u0000is vital for effective cancer treatment. The emergence of treatment techniques, such as stereotactic radiosurgery (SRS) and stereotactic \u0000radiotherapy (SRSR), significantly improved the disease prognosis. The use of high-tech radiation therapy in patients with oligometastases from breast carcinoma improves local control of intracranial lesions, prevents death, maintains the quality of life, and improves \u0000overall survival. \u0000The study aimed to analyze the results of key prospective studies on aspects of radiation therapy for breast cancer metastases to \u0000the brain. \u0000Methods: This review included key randomized trials on using radiation therapy for breast cancer metastases in the brain. The search \u0000was conducted in the PubMed database for 2005-2020 by the keywords “radiation therapy,” “breast cancer,” and “brain metastases.” \u0000Results: Reduced treatment time due to stereotactic radiosurgery and radiotherapy allows for maintaining productive life without expressed neurological symptoms. SRS is efficient in patients with up to five oligometastases in breast cancer. More metastases require total \u0000brain exposure, which is a poor prognostic factor. In prospective studies, SRS in breast cancer with brain metastases is recommended to \u0000improve the quality of life. \u0000Conclusion: The treatment of breast cancer with brain metastases requires a multidisciplinary approach based on the prevalence of \u0000the process, previous therapy, general somatic status, comorbidities, and available therapy options. Systemic therapy for breast cancer \u0000patients with brain metastases follows several schemes that demonstrate their therapeutic effectiveness.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"96 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75867836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET/CT IN ASSESSING THE LYMPHOMA RESPONSE TO TREATMENT Pet / ct评估淋巴瘤对治疗的反应
Pub Date : 2022-03-31 DOI: 10.52532/2521-6414-2022-1-63-32-35
Yulduzkhan Dauytova, Zhamilya Zholdybay, Zh. Zhakenova, J. Amankulov, S. Baigulova
Relevance: PET/CT has become an integral part of the diagnostic algorithm in lymphoma patients since lymphomas actively accumulate 18F-FDG. The high accuracy of PET/CT in patients with certain lymphoma types allows effective use of this method in clinical practice for diagnosis, staging, re-staging, evaluating the effectiveness of treatment, and determining further patient management tactics. The study aimed to evaluate the PET/CT capacity in assessing lymphoma treatment effectiveness. Methods: We conducted a retrospective analysis of PET/CT 18F-FDG results in 109 patients with a verified lymphoma diagnosis. The patients underwent PET/CT examinations at “Orhun Medical” PET/CT center based in the JSC “Kazakh Institute of Oncology and Radiology” (Almaty, Kazakhstan). Results: According to PET/CT results in assessing the lymphoma treatment effectiveness, the stabilization of the process was achieved in 38.5% of cases, progression – in 33.03%, a partial metabolic response – in 18.35%, and a complete response – in 10.09% of cases. Conclusion: PET/CT is the method of choice for evaluating the effectiveness of lymphoma treatment compared to other radiological techniques. PET/CT is based on determining metabolic treatment response, not only on size indicators. It plays an essential role in different stages of lymphoma treatment, providing new opportunities for personalized treatment
相关性:由于淋巴瘤主动积累18F-FDG, PET/CT已成为淋巴瘤患者诊断算法中不可或缺的一部分。PET/CT对某些淋巴瘤类型患者的高准确性使得该方法在临床实践中可以有效地用于诊断、分期、再分期、评估治疗效果以及确定进一步的患者管理策略。本研究旨在评估PET/CT在评估淋巴瘤治疗效果方面的能力。方法:我们对109例确诊为淋巴瘤的患者的PET/CT 18F-FDG结果进行回顾性分析。患者在“哈萨克斯坦肿瘤和放射学研究所”JSC(哈萨克斯坦阿拉木图)的“Orhun Medical”PET/CT中心接受了PET/CT检查。结果:根据评估淋巴瘤治疗效果的PET/CT结果,38.5%的病例实现了过程稳定,33.03%的病例实现了进展,18.35%的病例实现了部分代谢缓解,10.09%的病例实现了完全缓解。结论:与其他放射技术相比,PET/CT是评价淋巴瘤治疗效果的首选方法。PET/CT是基于确定代谢治疗反应,而不仅仅是尺寸指标。它在淋巴瘤治疗的不同阶段起着至关重要的作用,为个性化治疗提供了新的机会
{"title":"PET/CT IN ASSESSING THE LYMPHOMA RESPONSE \u0000TO TREATMENT","authors":"Yulduzkhan Dauytova, Zhamilya Zholdybay, Zh. Zhakenova, J. Amankulov, S. Baigulova","doi":"10.52532/2521-6414-2022-1-63-32-35","DOIUrl":"https://doi.org/10.52532/2521-6414-2022-1-63-32-35","url":null,"abstract":"Relevance: PET/CT has become an integral part of the diagnostic algorithm in lymphoma patients since lymphomas actively accumulate 18F-FDG. The high accuracy of PET/CT in patients with certain lymphoma types allows effective use of this method in clinical practice \u0000for diagnosis, staging, re-staging, evaluating the effectiveness of treatment, and determining further patient management tactics. \u0000The study aimed to evaluate the PET/CT capacity in assessing lymphoma treatment effectiveness. \u0000Methods: We conducted a retrospective analysis of PET/CT 18F-FDG results in 109 patients with a verified lymphoma diagnosis. The \u0000patients underwent PET/CT examinations at “Orhun Medical” PET/CT center based in the JSC “Kazakh Institute of Oncology and Radiology” (Almaty, Kazakhstan). \u0000Results: According to PET/CT results in assessing the lymphoma treatment effectiveness, the stabilization of the process was achieved \u0000in 38.5% of cases, progression – in 33.03%, a partial metabolic response – in 18.35%, and a complete response – in 10.09% of cases. \u0000Conclusion: PET/CT is the method of choice for evaluating the effectiveness of lymphoma treatment compared to other radiological \u0000techniques. PET/CT is based on determining metabolic treatment response, not only on size indicators. It plays an essential role in different \u0000stages of lymphoma treatment, providing new opportunities for personalized treatment","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81565002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EXPERIENCE IN CORRECTING POST-RADIATION STRICTURE OF THE URETER BY THE VERMIX: A CLINICAL CASE 放射治疗后输尿管狭窄的临床治疗体会
Pub Date : 2022-03-31 DOI: 10.52532/2663-4864-2022-1-63-51-55
N. Tabynbaev, T. Kurmanov, A. Digay, ShB. Mugalbekov, A. Mukazhanov, U. Zhanybyrbekuly, D. Mustafinov
Relevance: Restoration of ureteral patency in patients with extended defects is one of the most challenging problems in urology. Post-radiation strictures and iatrogenic injuries of the ureter during surgical interventions on the small pelvis and abdominal cavity organs are quite common in urological practice. In cases where it is impossible to restore the ureter with the help of one’s own tissues or the bladder, one of the possible interventions is the use of the appendix due to the similarity in the wall’s structure and peristaltic ability. The article aimed to describe the technique of appendicoureteroplasty (AUP) for post-radiation ureteral strictures. Methods: The article describes a clinical case of a surgical intervention to replace a part of the right ureter in a patient with an extended ureteral defect at the clinic of the National Research Cancer Center (Nur-Sultan, Kazakhstan). Results: The article presents the results of surgical treatment of a patient with extended post-radiation stricture of the ureter using the appendix on the mesentery. The effectiveness of restoring the urodynamics of the upper urinary tract has been shown. Conclusions: The obtained data shows that replacing the ureter with the vermix reduces the risk of hydronephrosis and improves the kidneys’ incretory and excretory functions.
相关性:输尿管延伸缺损患者输尿管通畅的修复是泌尿外科最具挑战性的问题之一。输尿管放射后狭窄及医源性损伤在泌尿外科手术中非常常见。在无法借助自身组织或膀胱恢复输尿管的情况下,由于阑尾壁的结构和蠕动能力相似,可能的干预措施之一是使用阑尾。本文旨在描述阑尾输尿管成形术治疗放射后输尿管狭窄的技术。方法:本文描述了在国家癌症研究中心(努尔苏丹,哈萨克斯坦)的临床病例,手术干预,以取代部分右输尿管延长缺陷的病人。结果:本文报道一例放射治疗后输尿管延伸性狭窄患者经肠系膜阑尾手术治疗的结果。恢复上尿路尿动力学的有效性已被证明。结论:本研究结果表明,输尿管置换可降低肾积水的发生风险,改善肾脏的排泄功能。
{"title":"EXPERIENCE IN CORRECTING POST-RADIATION STRICTURE OF THE URETER BY THE VERMIX: A CLINICAL CASE","authors":"N. Tabynbaev, T. Kurmanov, A. Digay, ShB. Mugalbekov, A. Mukazhanov, U. Zhanybyrbekuly, D. Mustafinov","doi":"10.52532/2663-4864-2022-1-63-51-55","DOIUrl":"https://doi.org/10.52532/2663-4864-2022-1-63-51-55","url":null,"abstract":"Relevance: Restoration of ureteral patency in patients with extended defects is one of the most challenging problems in urology. \u0000Post-radiation strictures and iatrogenic injuries of the ureter during surgical interventions on the small pelvis and abdominal cavity \u0000organs are quite common in urological practice. In cases where it is impossible to restore the ureter with the help of one’s own tissues or \u0000the bladder, one of the possible interventions is the use of the appendix due to the similarity in the wall’s structure and peristaltic ability. \u0000The article aimed to describe the technique of appendicoureteroplasty (AUP) for post-radiation ureteral strictures. \u0000Methods: The article describes a clinical case of a surgical intervention to replace a part of the right ureter in a patient with an extended ureteral defect at the clinic of the National Research Cancer Center (Nur-Sultan, Kazakhstan). \u0000Results: The article presents the results of surgical treatment of a patient with extended post-radiation stricture of the ureter using the \u0000appendix on the mesentery. The effectiveness of restoring the urodynamics of the upper urinary tract has been shown. \u0000Conclusions: The obtained data shows that replacing the ureter with the vermix reduces the risk of hydronephrosis and improves the \u0000kidneys’ incretory and excretory functions.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77777263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PROCALCITONIN DETERMINATION IN ONCOLOGY – RESULTS AND PROSPECTS: A LITERATURE REVIEW 降钙素原在肿瘤学中的测定——结果与展望:文献综述
Pub Date : 2022-03-31 DOI: 10.52532/2521-6414-2022-1-63-81-86
T. Sadykova, M. Kuzikeev, B. Sarsembaev, E. Orazbek
Relevance: Modern requirements for laboratory diagnostics of complicated courses of diseases provide for using highly specific and high-tech research methods like determining the level of procalcitonin (PCT). The PCT level increases only with the generalization of a bacterial infection and reflects the degree of generalization. Of practical value are an increase in the PCT level and the degree of such increase, a progressive increase, or a long-term (more than 3-5 days) high level. The assessment of this data over time, in combination with the changes in other clinical and laboratory parameters, allows for timely diagnosis and prediction of the outcome of the disease. The study aimed to assess the feasibility of the PCT level dynamic control for timely diagnosis of the overlay or generalization of an infectious process in the form of septic complications in cancer patients. Methods: A thematic search was carried out by keywords in the journal Malignant Tumors and Cochrane, PubMed, Oncology.ru, elibrary.ru, Medscape, and NCBI databases and libraries. We analyzed the results of studies of changes in PCT dynamics in oncological patients who developed and generalized a nonspecific infectious process that proceeded in the form of septic complications. Results: The need to determine the PCT level and its inclusion in the diagnostic algorithms has been confirmed in various research papers. The reliability and significance of these studies correspond to the highest levels of evidence-based medicine. PCT shows its high specificity in identifying the infectious component compared to other less informative indicators in oncological pathologies, such as the level of leukocytosis, CRP, and others. In some tumor processes, the initial level of PCT may be higher than the average (0.5 ng/l), but dynamic control will show the effectiveness of the therapeutic measures taken and the direction of development of the infectious process. The frequency and intervals of determining the PCT level are of particular importance. In some instances, if an infectious component is suspected in risk groups, the PCT level determination could be included in the initial examination algorithm. Conclusion: Despite the ambiguity of the PCT study results in oncological practice, the determination of systemic inflammation biomarkers in complex antitumor therapy will allow timely setting of indications for prescribing or intensifying antibiotic therapy, predicting the duration, and monitoring its effectiveness in oncological patients.
相关性:对复杂病程的实验室诊断的现代要求要求使用高度特异性和高科技的研究方法,如测定降钙素原(PCT)水平。PCT水平仅随着细菌感染的普遍化而增加,反映了普遍化的程度。具有实用价值的是PCT水平的增加和这种增加的程度,渐进式增加或长期(超过3-5天)高水平。随着时间的推移对这些数据的评估,结合其他临床和实验室参数的变化,可以及时诊断和预测疾病的结果。本研究旨在评估PCT水平动态控制的可行性,以及时诊断癌症患者脓毒性并发症形式的感染过程的叠加或推广。方法:在恶性肿瘤杂志和Cochrane、PubMed、Oncology.ru、library.ru、Medscape和NCBI数据库和图书馆中进行主题性检索。我们分析了肿瘤患者PCT动态变化的研究结果,这些患者以脓毒症并发症的形式发展并普遍化了非特异性感染过程。结果:各种研究论文都证实了确定PCT水平并将其纳入诊断算法的必要性。这些研究的可靠性和重要性符合循证医学的最高水平。与其他肿瘤病理指标(如白细胞水平、CRP水平等)相比,PCT在识别感染性成分方面具有很高的特异性。在某些肿瘤过程中,PCT的初始水平可能高于平均水平(0.5 ng/l),但动态控制将显示所采取治疗措施的有效性和感染过程的发展方向。确定PCT级别的频率和间隔特别重要。在某些情况下,如果在危险人群中怀疑存在感染成分,PCT水平的确定可包括在初始检查算法中。结论:尽管PCT研究结果在肿瘤实践中存在歧义,但在复杂的抗肿瘤治疗中,测定全身炎症生物标志物将有助于及时确定处方或加强抗生素治疗的适应症,预测持续时间,并监测其在肿瘤患者中的有效性。
{"title":"PROCALCITONIN DETERMINATION IN ONCOLOGY – RESULTS AND PROSPECTS: \u0000A LITERATURE REVIEW","authors":"T. Sadykova, M. Kuzikeev, B. Sarsembaev, E. Orazbek","doi":"10.52532/2521-6414-2022-1-63-81-86","DOIUrl":"https://doi.org/10.52532/2521-6414-2022-1-63-81-86","url":null,"abstract":"Relevance: Modern requirements for laboratory diagnostics of complicated courses of diseases provide for using highly specific and high-tech \u0000research methods like determining the level of procalcitonin (PCT). The PCT level increases only with the generalization of a bacterial infection \u0000and reflects the degree of generalization. Of practical value are an increase in the PCT level and the degree of such increase, a progressive increase, \u0000or a long-term (more than 3-5 days) high level. The assessment of this data over time, in combination with the changes in other clinical and laboratory parameters, allows for timely diagnosis and prediction of the outcome of the disease. \u0000The study aimed to assess the feasibility of the PCT level dynamic control for timely diagnosis of the overlay or generalization of an infectious \u0000process in the form of septic complications in cancer patients. \u0000Methods: A thematic search was carried out by keywords in the journal Malignant Tumors and Cochrane, PubMed, Oncology.ru, elibrary.ru, \u0000Medscape, and NCBI databases and libraries. \u0000We analyzed the results of studies of changes in PCT dynamics in oncological patients who developed and generalized a nonspecific infectious \u0000process that proceeded in the form of septic complications. \u0000Results: The need to determine the PCT level and its inclusion in the diagnostic algorithms has been confirmed in various research papers. The \u0000reliability and significance of these studies correspond to the highest levels of evidence-based medicine. \u0000PCT shows its high specificity in identifying the infectious component compared to other less informative indicators in oncological pathologies, \u0000such as the level of leukocytosis, CRP, and others. \u0000In some tumor processes, the initial level of PCT may be higher than the average (0.5 ng/l), but dynamic control will show the effectiveness of \u0000the therapeutic measures taken and the direction of development of the infectious process. \u0000The frequency and intervals of determining the PCT level are of particular importance. In some instances, if an infectious component is suspected in risk groups, the PCT level determination could be included in the initial examination algorithm. \u0000Conclusion: Despite the ambiguity of the PCT study results in oncological practice, the determination of systemic inflammation biomarkers in \u0000complex antitumor therapy will allow timely setting of indications for prescribing or intensifying antibiotic therapy, predicting the duration, and \u0000monitoring its effectiveness in oncological patients.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84462846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COMPUTED TOMOGRAPHY FEATURES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASSOCIATED WITH LUNG CANCER 慢性阻塞性肺疾病与肺癌相关的计算机断层扫描特征
Pub Date : 2022-03-31 DOI: 10.52532/2521-6414-2022-1-63-36-40
Y. Filippenko, Z. Amankulov, Zhamilya Zholdybay, Zh. Zhakenova, A. Panina, S. Kasenova
Relevance: Chronic obstructive pulmonary disease (COPD) associated with lung cancer is common in smoking patients. Computed tomography (CT) is vital in detecting lung cancer, assessing regional lung parenchymal destruction, and airway remodeling in COPD. ДИАГНОСТИКА 40 Онкология и радиология Казахстана, №1 (63) 2022 The study aimed to determine the CT features of COPD associated with lung cancer. Methods: This retrospective study included chest CT exams of 56 patients over the age of 40, with a smoking history of 10 years and more and with suspected COPD. 46.43% of patients had CT signs of lung cancer associated with COPD. Results: Barrel-shaped chest (19.23%), saber-sheath trachea (7.69%), and bronchiectasis (15.38%) were less common in patients with lung cancer. Paraseptal and centrilobular emphysema were diagnosed in 96.15%, bullae – 73.33%. Bronchial narrowing of the lumen and wall thickening were identified for all lobar bronchus, segmental bronchus, and subsegmental bronchus. Conclusion: Paraseptal and centrilobular emphysema and bullae in the upper lobes of lungs were predominant CT features in patients with COPD associated with lung cancer. Lumen narrowing and wall thickening of lobar bronchus, segmental bronchus, and subsegmental bronchus were also revealed.
相关性:肺癌相关的慢性阻塞性肺疾病(COPD)在吸烟患者中很常见。计算机断层扫描(CT)在发现肺癌,评估区域性肺实质破坏和COPD气道重塑方面至关重要。ДИАГНОСТИКА40ОнкологияирадиологияКазахстана,№1(63)2022研究旨在确定慢性阻塞性肺病的CT特征与肺癌有关。方法:本回顾性研究包括56例40岁以上、吸烟史10年及以上、疑似COPD患者的胸部CT检查。46.43%的患者有肺癌合并COPD的CT征象。结果:肺癌患者中桶状胸(19.23%)、马刀鞘气管(7.69%)、支气管扩张(15.38%)较少见。膈旁肺气肿、小叶中心肺气肿占96.15%,大疱性肺气肿占73.33%。支气管管腔狭窄和管壁增厚在所有叶状支气管、段状支气管和亚段状支气管中均有发现。结论:肺膈旁肺气肿、小叶中心肺气肿及肺上叶大泡是COPD合并肺癌患者的主要CT表现。叶支气管、节段支气管、亚节段支气管均可见管腔狭窄、壁增厚。
{"title":"COMPUTED TOMOGRAPHY FEATURES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE \u0000ASSOCIATED WITH LUNG CANCER","authors":"Y. Filippenko, Z. Amankulov, Zhamilya Zholdybay, Zh. Zhakenova, A. Panina, S. Kasenova","doi":"10.52532/2521-6414-2022-1-63-36-40","DOIUrl":"https://doi.org/10.52532/2521-6414-2022-1-63-36-40","url":null,"abstract":"Relevance: Chronic obstructive pulmonary disease (COPD) associated with lung cancer is common in smoking patients. Computed tomography (CT) is vital in detecting lung cancer, assessing regional lung parenchymal destruction, and airway remodeling in COPD. \u0000ДИАГНОСТИКА \u000040 Онкология и радиология Казахстана, №1 (63) 2022 \u0000The study aimed to determine the CT features of COPD associated with lung cancer. \u0000Methods: This retrospective study included chest CT exams of 56 patients over the age of 40, with a smoking history of 10 years and more and \u0000with suspected COPD. 46.43% of patients had CT signs of lung cancer associated with COPD. \u0000Results: Barrel-shaped chest (19.23%), saber-sheath trachea (7.69%), and bronchiectasis (15.38%) were less common in patients with lung \u0000cancer. Paraseptal and centrilobular emphysema were diagnosed in 96.15%, bullae – 73.33%. Bronchial narrowing of the lumen and wall thickening were identified for all lobar bronchus, segmental bronchus, and subsegmental bronchus. \u0000Conclusion: Paraseptal and centrilobular emphysema and bullae in the upper lobes of lungs were predominant CT features in patients with \u0000COPD associated with lung cancer. Lumen narrowing and wall thickening of lobar bronchus, segmental bronchus, and subsegmental bronchus \u0000were also revealed.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77219524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PROCALCITONIN DETERMINATION IN ONCOLOGY – RESULTS AND PROSPECTS: A LITERATURE REVIEW 降钙素原在肿瘤学中的测定——结果与展望:文献综述
Pub Date : 2022-03-31 DOI: 10.52532/2663-4864-2022-1-63-81-86
T. Sadykova, M. Kuzikeev, B. Sarsembaev, E. Orazbek
Relevance: Modern requirements for laboratory diagnostics of complicated courses of diseases provide for using particular and hightech research methods like determining the level of procalcitonin (PCT). The PCT level increases only with the generalization of a bacterial infection and reflects the degree of abstraction. Of practical value are an increase in the PCT level and the degree of such increase, a progressive increase, or a long-term (more than 3-5 days) high level. The assessment of this data over time, in combination with the changes in other clinical and laboratory parameters, allows for timely diagnosis and prediction of the outcome of the disease. The study aimed to assess the feasibility of the PCT level dynamic control for timely diagnosis of the overlay or generalization of an infectious process in the form of septic complications in cancer patients. Methods: A thematic search was carried out by keywords in the journal Malignant Tumors and Cochrane, PubMed, Oncology.ru, elibrary.ru, Medscape, and NCBI databases and libraries. We analyzed the results of studies of changes in PCT dynamics in oncological patients who developed and generalized a nonspecific infectious process that proceeded in the form of septic complications. Results: Various research papers have confirmed the need to determine the PCT level and its inclusion in the diagnostic algorithms. The reliability and significance of these studies correspond to the highest levels of evidence-based medicine. PCT shows its high specificity in identifying the infectious component compared to other less informative indicators in oncological pathologies, such as the level of leukocytosis, CRP, and others. In some tumor processes, the initial level of PCT may be higher than the average (0.5 ng/l). Still, dynamic control will show the effectiveness of the therapeutic measures taken and the direction of development of the infectious process. The frequency and intervals of determining the PCT level are of particular importance. In some instances, if an infectious component is suspected in risk groups, the PCT level determination could be included in the initial examination algorithm. Conclusion: Despite the ambiguity of the PCT study results in oncological practice, the determination of systemic inflammation biomarkers in complex antitumor therapy will allow timely setting of indications for prescribing or intensifying antibiotic treatment, predicting the duration, and monitoring its effectiveness in oncological patients.
相关性:对复杂病程的实验室诊断的现代要求要求使用特定的和高科技的研究方法,如测定降钙素原(PCT)水平。PCT水平仅随着细菌感染的普遍化而增加,并反映了抽象程度。具有实用价值的是PCT水平的增加和这种增加的程度,渐进式增加或长期(超过3-5天)高水平。随着时间的推移对这些数据的评估,结合其他临床和实验室参数的变化,可以及时诊断和预测疾病的结果。本研究旨在评估PCT水平动态控制的可行性,以及时诊断癌症患者脓毒性并发症形式的感染过程的叠加或推广。方法:在恶性肿瘤杂志和Cochrane、PubMed、Oncology.ru、library.ru、Medscape和NCBI数据库和图书馆中进行主题性检索。我们分析了肿瘤患者PCT动态变化的研究结果,这些患者以脓毒症并发症的形式发展并普遍化了非特异性感染过程。结果:多篇研究论文均证实有必要确定PCT水平并将其纳入诊断算法。这些研究的可靠性和重要性符合循证医学的最高水平。与其他肿瘤病理指标(如白细胞水平、CRP水平等)相比,PCT在识别感染性成分方面具有很高的特异性。在某些肿瘤过程中,PCT的初始水平可能高于平均值(0.5 ng/l)。然而,动态控制将显示所采取的治疗措施的有效性和感染过程的发展方向。确定PCT级别的频率和间隔特别重要。在某些情况下,如果在危险人群中怀疑存在感染成分,PCT水平的确定可包括在初始检查算法中。结论:尽管PCT研究结果在肿瘤实践中存在歧义,但在复杂的抗肿瘤治疗中,测定全身炎症生物标志物将有助于及时确定处方或加强抗生素治疗的适应症,预测持续时间,并监测其在肿瘤患者中的有效性。
{"title":"PROCALCITONIN DETERMINATION IN ONCOLOGY – RESULTS AND PROSPECTS: A LITERATURE REVIEW","authors":"T. Sadykova, M. Kuzikeev, B. Sarsembaev, E. Orazbek","doi":"10.52532/2663-4864-2022-1-63-81-86","DOIUrl":"https://doi.org/10.52532/2663-4864-2022-1-63-81-86","url":null,"abstract":"Relevance: Modern requirements for laboratory diagnostics of complicated courses of diseases provide for using particular and hightech research methods like determining the level of procalcitonin (PCT). The PCT level increases only with the generalization of a bacterial \u0000infection and reflects the degree of abstraction. Of practical value are an increase in the PCT level and the degree of such increase, a progressive increase, or a long-term (more than 3-5 days) high level. The assessment of this data over time, in combination with the changes \u0000in other clinical and laboratory parameters, allows for timely diagnosis and prediction of the outcome of the disease. \u0000The study aimed to assess the feasibility of the PCT level dynamic control for timely diagnosis of the overlay or generalization of an \u0000infectious process in the form of septic complications in cancer patients. \u0000Methods: A thematic search was carried out by keywords in the journal Malignant Tumors and Cochrane, PubMed, Oncology.ru, \u0000elibrary.ru, Medscape, and NCBI databases and libraries. \u0000We analyzed the results of studies of changes in PCT dynamics in oncological patients who developed and generalized a nonspecific \u0000infectious process that proceeded in the form of septic complications. \u0000Results: Various research papers have confirmed the need to determine the PCT level and its inclusion in the diagnostic algorithms. \u0000The reliability and significance of these studies correspond to the highest levels of evidence-based medicine. \u0000PCT shows its high specificity in identifying the infectious component compared to other less informative indicators in oncological \u0000pathologies, such as the level of leukocytosis, CRP, and others. \u0000In some tumor processes, the initial level of PCT may be higher than the average (0.5 ng/l). Still, dynamic control will show the effectiveness of the therapeutic measures taken and the direction of development of the infectious process. \u0000The frequency and intervals of determining the PCT level are of particular importance. In some instances, if an infectious component \u0000is suspected in risk groups, the PCT level determination could be included in the initial examination algorithm. \u0000Conclusion: Despite the ambiguity of the PCT study results in oncological practice, the determination of systemic inflammation biomarkers in complex antitumor therapy will allow timely setting of indications for prescribing or intensifying antibiotic treatment, predicting \u0000the duration, and monitoring its effectiveness in oncological patients.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74413609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EPIDEMIOLOGICAL ASPECTS OF COLORECTAL CANCER IN THE REPUBLIC OF KAZAKHSTAN 哈萨克斯坦共和国结直肠癌的流行病学方面
Pub Date : 2022-03-31 DOI: 10.52532/2521-6414-2022-1-63-25-31
А. Khozhayev, D. Kaidarova, T. Sadykova, A. Rubanova
Relevance: Colorectal cancer is one of today’s most critical health issues globally and in the Republic of Kazakhstan. Taking leading positions in the general structure of oncopathology, this nosological form of tumors forces clinicians to develop ways to improve statistical indicators. ЭПИДЕМИОЛОГИЯ Онкология и радиология Казахстана, №1 (63) 2022 31 Purpose of the article – to review the epidemiological aspects of colorectal cancer in the Republic of Kazakhstan in 2011-2020. Results: We revealed an increase in the share of early (I-II) stage colon and rectal cancer cases. The share of early stages of rectal cancer was 61.5% in 2011 compared to 68.5% in 2020; in colon cancer, it was 36.5% and 53.1%, respectively. The share of advanced (locally advanced) stage III cases of visually accessible rectal cancer has decreased from 25.2% in 2011 to 18.3% in 2020. The overall 5-year survival in 2020 amounted to 50.7% for colon cancer and 46.0% for rectal cancer, and these were the best rates in the entire decade. We also found territorial specifics in this pathology incidence. The one-year and overall mortality from these diseases have decreased, amounting to 29.2 in 2011 and 18.8 in 2020 for rectal cancer, 31.9 and 19.8 for colon cancer, 4.5 and 3.9 in rectal cancer, 4.8 and 4.1 in colon cancer, respectively. Conclusions: An analytical assessment of the statistical indicators of colorectal cancer over the decade showed that there are regions that excel in incidence rates from year to year. At the same time, indicators of early diagnosis and overall 5-year survival have improved, and one-year and overall mortality has decreased.
相关性:结直肠癌是当今全球和哈萨克斯坦共和国最关键的健康问题之一。在肿瘤病理学的总体结构中处于领先地位,这种肿瘤的分类学形式迫使临床医生开发改进统计指标的方法。ЭПИДЕМИОЛОГИЯ Онкология радиология Казахстана,№1(63)2022 31文章的目的-回顾2011-2020年哈萨克斯坦共和国结直肠癌的流行病学方面。结果:我们发现早期(I-II)期结肠癌和直肠癌病例的比例有所增加。2011年早期直肠癌的比例为61.5%,而2020年为68.5%;在结肠癌中,分别为36.5%和53.1%。晚期(局部晚期)III期直肠癌的比例从2011年的25.2%下降到2020年的18.3%。到2020年,结肠癌的总体5年生存率为50.7%,直肠癌为46.0%,这是整个十年来的最佳生存率。我们还发现了这种病理发病率的地域特征。这些疾病的年死亡率和总死亡率有所下降,2011年为29.2人,2020年为18.8人,结肠癌为31.9人和19.8人,直肠癌为4.5人和3.9人,结肠癌为4.8人和4.1人。结论:对近十年来结直肠癌统计指标的分析评估表明,每年的发病率都有优势的地区。与此同时,早期诊断指标和5年总生存率有所提高,1年死亡率和总死亡率有所下降。
{"title":"EPIDEMIOLOGICAL ASPECTS OF COLORECTAL CANCER \u0000IN THE REPUBLIC OF KAZAKHSTAN","authors":"А. Khozhayev, D. Kaidarova, T. Sadykova, A. Rubanova","doi":"10.52532/2521-6414-2022-1-63-25-31","DOIUrl":"https://doi.org/10.52532/2521-6414-2022-1-63-25-31","url":null,"abstract":"Relevance: Colorectal cancer is one of today’s most critical health issues globally and in the Republic of Kazakhstan. Taking leading positions \u0000in the general structure of oncopathology, this nosological form of tumors forces clinicians to develop ways to improve statistical indicators. \u0000ЭПИДЕМИОЛОГИЯ \u0000Онкология и радиология Казахстана, №1 (63) 2022 31 \u0000Purpose of the article – to review the epidemiological aspects of colorectal cancer in the Republic of Kazakhstan in 2011-2020. \u0000Results: We revealed an increase in the share of early (I-II) stage colon and rectal cancer cases. The share of early stages of rectal cancer was \u000061.5% in 2011 compared to 68.5% in 2020; in colon cancer, it was 36.5% and 53.1%, respectively. \u0000The share of advanced (locally advanced) stage III cases of visually accessible rectal cancer has decreased from 25.2% in 2011 to 18.3% in \u00002020. The overall 5-year survival in 2020 amounted to 50.7% for colon cancer and 46.0% for rectal cancer, and these were the best rates in the \u0000entire decade. We also found territorial specifics in this pathology incidence. \u0000The one-year and overall mortality from these diseases have decreased, amounting to 29.2 in 2011 and 18.8 in 2020 for rectal cancer, 31.9 and \u000019.8 for colon cancer, 4.5 and 3.9 in rectal cancer, 4.8 and 4.1 in colon cancer, respectively. \u0000Conclusions: An analytical assessment of the statistical indicators of colorectal cancer over the decade showed that there are regions that \u0000excel in incidence rates from year to year. At the same time, indicators of early diagnosis and overall 5-year survival have improved, and one-year \u0000and overall mortality has decreased.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"108 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87623585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ADVANTAGES AND PROSPECTS OF TARGETED THERAPY IN ONCOLOGICAL PRACTICE: A literature review 肿瘤靶向治疗的优势与前景:文献综述
Pub Date : 2022-03-31 DOI: 10.52532/2521-6414-2022-1-63-70-80
A. Murina, А. Uaisova, A. Ergalieva
Relevance: Cancer is the second leading cause of death globally and is expected to be responsible for approximately 19.3 million new cases and 10 million deaths in 2021. With an unprecedented understanding of the molecular pathways that drive the development and progression of human cancers, novel targeted therapies have become an exciting new development for anti-cancer medicine. These targeted therapies, also known as biologic therapies, have become a primary treatment modality by blocking the growth of cancer cells by specifically targeting molecules required for cell growth and tumorigenesis. Due to their specificity, these new therapies are expected to have better efficacy and limited adverse side effects compared to other treatment options, including hormonal and cytotoxic therapies. The study aimed to provide a detailed overview of the advantages and prospects of using targeted therapy in oncological practice. Мethods: The search was carried out in the following databases: Scopus, Medline, Cochrane, PubMed, ScienceDirect for 2016-2021. Sources were searched for the following keywords: clinical trials, immunotherapy, monoclonal antibodies, small molecular weight inhibitors, targeted therapy. Results: This review explores the clinical development, successes, and challenges facing targeted anti-cancer therapies, including both small molecule inhibitors and antibody-targeted therapies. The authors describe targeted therapies to epidermal growth factor receptor, vascular endothelial growth factor, human epidermal growth factor receptor 2, anaplastic lymphoma kinase, BRAF, T-cell mediated immune response inhibitors, cytotoxic T-lymphocyte-associated protein 4, and programmed cell death protein-1/PD-1 ligand. Conclusion: Over the past decade, there have been significant changes in cancer treatment, including targeted therapy, which has become more common. However, in monotherapy, targeted drugs show low activity. In addition, the selection of patients for targeted therapy remains a difficult task since there are not enough reliable biomarkers to predict the action of most targeted agents. This requires a deeper study of molecular biology, namely signaling pathways that determine the pathogenesis of oncological diseases.
相关性:癌症是全球第二大死亡原因,预计2021年将造成约1930万新病例和1000万死亡。随着对驱动人类癌症发展和进展的分子途径的前所未有的理解,新的靶向治疗已经成为抗癌医学的一个令人兴奋的新发展。这些靶向治疗,也被称为生物治疗,通过特异性靶向细胞生长和肿瘤发生所需的分子来阻断癌细胞的生长,已经成为一种主要的治疗方式。由于它们的特异性,与其他治疗方案(包括激素和细胞毒性治疗)相比,这些新疗法有望具有更好的疗效和有限的不良副作用。本研究旨在提供肿瘤实践中使用靶向治疗的优势和前景的详细概述。Мethods:检索在以下数据库中进行:Scopus, Medline, Cochrane, PubMed, ScienceDirect 2016-2021年。检索了以下关键词:临床试验,免疫治疗,单克隆抗体,小分子量抑制剂,靶向治疗。结果:本文综述了靶向抗癌治疗的临床发展、成功和面临的挑战,包括小分子抑制剂和抗体靶向治疗。作者描述了针对表皮生长因子受体、血管内皮生长因子、人表皮生长因子受体2、间变性淋巴瘤激酶、BRAF、t细胞介导的免疫反应抑制剂、细胞毒性t淋巴细胞相关蛋白4和程序性细胞死亡蛋白-1/PD-1配体的靶向治疗。结论:在过去的十年中,癌症治疗发生了重大变化,包括靶向治疗,它已经变得越来越普遍。然而,在单一疗法中,靶向药物表现出低活性。此外,选择接受靶向治疗的患者仍然是一项艰巨的任务,因为没有足够可靠的生物标志物来预测大多数靶向药物的作用。这需要对分子生物学进行更深入的研究,即决定肿瘤疾病发病机制的信号通路。
{"title":"ADVANTAGES AND PROSPECTS OF TARGETED THERAPY IN ONCOLOGICAL PRACTICE: \u0000A literature review","authors":"A. Murina, А. Uaisova, A. Ergalieva","doi":"10.52532/2521-6414-2022-1-63-70-80","DOIUrl":"https://doi.org/10.52532/2521-6414-2022-1-63-70-80","url":null,"abstract":"Relevance: Cancer is the second leading cause of death globally and is expected to be responsible for approximately 19.3 million new cases \u0000and 10 million deaths in 2021. With an unprecedented understanding of the molecular pathways that drive the development and progression of \u0000human cancers, novel targeted therapies have become an exciting new development for anti-cancer medicine. These targeted therapies, also known \u0000as biologic therapies, have become a primary treatment modality by blocking the growth of cancer cells by specifically targeting molecules required \u0000for cell growth and tumorigenesis. Due to their specificity, these new therapies are expected to have better efficacy and limited adverse side effects \u0000compared to other treatment options, including hormonal and cytotoxic therapies. \u0000The study aimed to provide a detailed overview of the advantages and prospects of using targeted therapy in oncological practice. \u0000Мethods: The search was carried out in the following databases: Scopus, Medline, Cochrane, PubMed, ScienceDirect for 2016-2021. Sources \u0000were searched for the following keywords: clinical trials, immunotherapy, monoclonal antibodies, small molecular weight inhibitors, targeted therapy. \u0000Results: This review explores the clinical development, successes, and challenges facing targeted anti-cancer therapies, including both small \u0000molecule inhibitors and antibody-targeted therapies. The authors describe targeted therapies to epidermal growth factor receptor, vascular endothelial growth factor, human epidermal growth factor receptor 2, anaplastic lymphoma kinase, BRAF, T-cell mediated immune response inhibitors, \u0000cytotoxic T-lymphocyte-associated protein 4, and programmed cell death protein-1/PD-1 ligand. \u0000Conclusion: Over the past decade, there have been significant changes in cancer treatment, including targeted therapy, which has become \u0000more common. However, in monotherapy, targeted drugs show low activity. In addition, the selection of patients for targeted therapy remains a \u0000difficult task since there are not enough reliable biomarkers to predict the action of most targeted agents. This requires a deeper study of molecular \u0000biology, namely signaling pathways that determine the pathogenesis of oncological diseases.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83157874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PROBLEMS OF DRUG PROVISION FOR CANCER PATIENTS IN THE REPUBLIC OF KAZAKHSTAN 哈萨克斯坦共和国为癌症患者提供药物的问题
Pub Date : 2022-03-31 DOI: 10.52532/2663-4864-2022-1-63-11-16
O. Shatkovskaya
Relevance: Drug supply is a prerequisite for drug treatment of malignant neoplasms. Drug therapy is an essential component of cancer treatment. However, the potential of drug therapy is not the same in different human tumors. Providing an oncological patient with a full range of modern medicines is one of the main tasks of the healthcare system. Currently, the problem of the availability of drug provision for cancer patients is relevant. Today, there is a regional disparity in the provision of drug care in the country: the availability of drugs for patients is highly dependent on the economic development of the region of their residence. Drugs, exceedingly targeted drugs and immuno-oncology agents, are more available in the cities of republican significance and the capital city. The study aimed to analyze the problems and find ways to improve drug provision for cancer patients in the Republic of Kazakhstan. Methods included the analysis of the current drug provision for cancer patients in the Republic of Kazakhstan, identifying problematic issues, finding solutions, and developing correct unified approaches to determining the needs of cancer patients for drugs at all stages of care. The study results highlight the current drug supply problems for cancer patients and allow the development of ways to improve it, including in the context of combating the COVID-19 pandemic. Conclusion: Breakthrough technologies and new cancer treatment regimens appear almost every month. Therefore, it is essential to make balanced and rational decisions in this area, rather than applying simplified administrative schemes for orders and purchases. Today, the oncologists of Kazakhstan can choose therapy for each cancer patient when they possess the results of relevant molecular genetic studies, know the characteristics of the tumor and the body, and have а conclusion of the multidisciplinary team. All the above gives hope for a transition to a more humane attitude towards patients when the drug choice depends on the chosen therapy’s clinical efficacy and purposefulness instead of the drug origin or price. Unfortunately, the damage from ineffective drugs often exceeds the cost of effective medicines and technologies, while these effective drugs will not always be the most expensive. Therefore, choosing the treatment that a particular oncological patient needs is impressive art.
相关性:药物供应是恶性肿瘤药物治疗的前提。药物治疗是癌症治疗的重要组成部分。然而,药物治疗的潜力在不同的人类肿瘤中是不一样的。为肿瘤患者提供全方位的现代药物是医疗保健系统的主要任务之一。目前,癌症患者药物供应的可得性问题是相关的。今天,该国在提供药物保健方面存在地区差异:患者获得药物的情况高度依赖于其居住地区的经济发展。药物,极具针对性的药物和免疫肿瘤药物,在共和意义的城市和首都更容易获得。该研究旨在分析问题,并找到改善哈萨克斯坦共和国癌症患者药物供应的方法。方法包括分析哈萨克斯坦共和国目前为癌症患者提供的药物,确定问题,寻找解决方案,并制定正确的统一方法来确定癌症患者在所有护理阶段对药物的需求。该研究结果突出了目前癌症患者的药物供应问题,并允许开发改进方法,包括在抗击COVID-19大流行的背景下。结论:几乎每个月都有突破性技术和新的癌症治疗方案出现。因此,必须在这方面做出平衡和理性的决策,而不是对订单和采购采用简化的管理方案。如今,哈萨克斯坦的肿瘤学家在掌握相关分子遗传学研究结果,了解肿瘤和机体特点,并有多学科团队结论的情况下,可以为每一位癌症患者选择治疗方案。所有这些都给我们带来了希望,当药物的选择取决于所选择的治疗的临床疗效和目的,而不是药物的来源或价格时,对患者的态度会变得更加人性化。不幸的是,无效药物造成的损害往往超过有效药物和技术的成本,而这些有效药物并不总是最昂贵的。因此,选择特定肿瘤患者需要的治疗方法是一门令人印象深刻的艺术。
{"title":"PROBLEMS OF DRUG PROVISION FOR CANCER PATIENTS IN THE REPUBLIC OF KAZAKHSTAN","authors":"O. Shatkovskaya","doi":"10.52532/2663-4864-2022-1-63-11-16","DOIUrl":"https://doi.org/10.52532/2663-4864-2022-1-63-11-16","url":null,"abstract":"Relevance: Drug supply is a prerequisite for drug treatment of malignant neoplasms. Drug therapy is an essential component of cancer treatment. However, the potential of drug therapy is not the same in different human tumors. Providing an oncological patient with a full range of modern medicines is one of the main tasks of the healthcare system. Currently, the problem of the availability of drug provision for cancer patients is relevant. Today, there is a regional disparity in the provision of drug care in the country: the availability of drugs for \u0000patients is highly dependent on the economic development of the region of their residence. Drugs, exceedingly targeted drugs and immuno-oncology agents, are more available in the cities of republican significance and the capital city. \u0000The study aimed to analyze the problems and find ways to improve drug provision for cancer patients in the Republic of Kazakhstan. \u0000Methods included the analysis of the current drug provision for cancer patients in the Republic of Kazakhstan, identifying problematic issues, finding solutions, and developing correct unified approaches to determining the needs of cancer patients for drugs at all stages of care. \u0000The study results highlight the current drug supply problems for cancer patients and allow the development of ways to improve it, \u0000including in the context of combating the COVID-19 pandemic. \u0000Conclusion: Breakthrough technologies and new cancer treatment regimens appear almost every month. Therefore, it is essential to \u0000make balanced and rational decisions in this area, rather than applying simplified administrative schemes for orders and purchases. Today, the oncologists of Kazakhstan can choose therapy for each cancer patient when they possess the results of relevant molecular genetic studies, know the characteristics of the tumor and the body, and have а conclusion of the multidisciplinary team. All the above gives hope for a transition to a more humane attitude towards patients when the drug choice depends on the chosen therapy’s clinical efficacy and purposefulness instead of the drug origin or price. Unfortunately, the damage from ineffective drugs often exceeds the cost of effective medicines and technologies, while these effective drugs will not always be the most expensive. Therefore, choosing the treatment that a particular oncological patient needs is impressive art.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87458484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Oncologia i radiologia Kazakhstana
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1